Viehbacher’s Agenda: Biogen makes Leaps in the Fight Against Rare Autoimmune Diseases
With the appointment of new CEO, Christopher Viehbacher, New England Council member, Biogen is spearheading the fight against autoimmune and rare diseases.
Christopher Viehbacher has big plans for the future of Biogen. Viehbacher’s main goal is to expand the company’s expertise into untouched aspects of rare diseases while maintaining its focus on immunology. Most recently, Biogen has begun the commercialization of Lecanemab, an Alzheimer’s disease drug that the FDA recently approved. Biogen has also collaborated with Sage Therapeutics Inc. in the development of Zuranolone, a drug with the goal of alleviating symptoms of post-partum depression.
Viehbacher assures, “Lecanemab and Zuranolone — if we get those right, that’s going to account for an awful lot of the new Biogen.”
The New England Council commends Viehbacher for his work and is eager to see what Biogen will accomplish next.
Read more in the Boston Business Journal.